Loading quotes...

Forecast

Buy	18
Hold	20
Sell	4

News Go to news feed

Mallinckrodt completes acquisition of Endo and begins delisting process

Mallinckrodt has completed the acquisition of Endo, making Endo a wholly owned subsidiary of Mallinckrodt. As part of the transaction, Endo shares will be suspended from trading and the company will file for delisting with the SEC. There have also been changes in Endo's management and board of directors, including new appointments and severance arrangements. » More on de.investing.com
Endo presents positive study data and completes sale of international pharmaceuticals business

Endo has presented new data at a specialist conference on potential treatments for plantar fibromatosis and fasciitis, which showed improvements in patients during clinical trials. The company has also completed the sale of its international pharmaceuticals business to Knight Therapeutics and Paladin Pharma, marking an important step in its strategic realignment. Investors are closely monitoring these developments in light of the upcoming quarterly report and the company's financial situation. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Endo International has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last year, Endo International had revenue of €1.82B and net profit of -€2.22B

(EUR)	2023	YoY
Revenue	1.82B	15.83%
Gross profit	967.58M	19.43%
Net profit	-2.22B	18.68%
EBITDA	-1.89B	5.74%

Fundamentals

Metric	Value
Market capitalization	€88.96K
Number of shares	164.96M
52-week high/low	€0.0764 - €0.00
Dividends	No
Beta	0.80
P/E ratio	-0.15
PEG ratio	0.00
P/B ratio	-0.07
P/S ratio	0.00

Company profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.